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ABSTRACT
Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood 
and adolescence. Despite advances in therapy, patients with histological variant of 
rhabdomyosarcoma known as alveolar rhabdomyosarcoma (ARMS) have a 5-year 
survival of less than 30%. Caveolin-1 (CAV1), encoding the structural component of 
cellular caveolae, is a suggested tumor suppressor gene involved in cell signaling. 
In the present study we report that compared to other forms of rhabdomyosarcoma 
(RMS) CAV1 expression is either undetectable or very low in ARMS cell lines and tumor 
samples. DNA methylation analysis of the promoter region and azacytidine-induced 
re-expression suggest the involvement of epigenetic mechanisms in the silencing 
of CAV1. Reintroduction of CAV1 in three of these cell lines impairs their clonogenic 
capacity and promotes features of muscular differentiation. In vitro, CAV1-expressing 
cells show high expression of Caveolin-3 (CAV3), a muscular differentiation marker. 
Blockade of MAPK signaling is also observed. In vivo, CAV1-expressing xenografts 
show growth delay, features of muscular differentiation and increased cell death. In 
summary, our results suggest that CAV1 could function as a potent tumor suppressor 
in ARMS tumors. Inhibition of CAV1 function therefore, could contribute to aberrant 
cell proliferation, leading to ARMS development. 
INTRODUCTION
Rhabdomyosarcoma (RMS) is a rare soft tissue 
sarcoma, more frequent in children, accounting for 3-4% 
of childhood cancers. It is believed to be caused by the 
disruption of regulatory mechanisms that lead to the 
myogenic phenotype in primitive mesenchymal stem 
cells [1]. RMS comprises two histological subtypes, 
alveolar (ARMS) and embryonal (ERMS), each of 
them with different prognosis and various genetic and 
molecular alterations. ERMS typically occurs in the 
head, neck and genitourinary sites and is associated with 
loss of heterozygosity on the short arm of chromosome 
11 (the 11p15.5 region) which codify for various tumor 
suppressor genes [2-3] imprinted in physiological but 
not in pathologic conditions. ARMS, on the other hand, 
commonly arises in the trunk and extremities and is linked 
with acquired specific chromosomal translocations t(2;13)
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(q35;q14) or t(1;13)(p36;q14) in 70 to 85% of cases. These 
translocations give rise to the fusion of the PAX3 or PAX7 
transcription factor to the forkhead (FOXO1) transcription 
factor. All characterized PAX-FOXO1 chromosomal 
translocations generate structurally equivalent, in-frame 
PAX-FOXO1 chimeric transcription factors, where 
the PAX paired box and homeodomain DNA-binding 
domains are fused to the transcriptional activation domain 
of FOXO1 [4]. PAX3/7-FOXO1 aberrant fusion proteins 
behave as oncoproteins deregulating PAX3 and PAX7 
transcription factor networks that play a role in skeletal 
muscle development, thus altering aspects of the muscle 
development, growth and/or maintenance. In the end 
PAX/FOXO1 proteins drive neoplastic transformation 
of skeletal muscle lineage cells towards malignant, 
developmentally arrested primitive myoblasts [5].
Caveolin-1 (CAV1) is the principal structural 
protein responsible for the formation of caveolae in 
the cell membrane. The capacity of CAV1 to associate 
with a wide variety of proteins is crucial in a number 
of processes, ranging from vesicular transport and 
cholesterol homeostasis to nitric oxide production and cell 
migration, among others [6-9]. CAV1 has been thoroughly 
characterized in many cancers due to its ability to regulate 
cell cycle progression and intracellular signal transduction, 
and it has been shown to act both as a tumor suppressor 
or tumor promoter depending on the cellular background 
[10-12].
In a recent study, it was shown that CAV1 was 
predominantly expressed in the ERMS histotype and 
placed CAV1 as a valuable marker of diagnosis for RMS 
characterized by low degree of differentiation [13]. We 
further confirmed the absence of CAV1 in ARMS cell 
lines [12]. However, the mechanism responsible for 
CAV1 absence and its putative role in ARMS as a tumor 
suppressor has not been investigated yet. We show here 
that CAV1 silencing in ARMS cells is a consequence of 
promoter methylation. Additionally, we show that re-
expression of CAV1 in three of these cell lines is cytostatic 
and promotes features of muscular differentiation. In 
vivo, CAV1-expressing tumor cells show growth delay 
and higher muscular differentiation in comparison to 
untransfected and vector transfected cells. Our results 
demonstrate that CAV1 could function as a potent tumor 
suppressor in ARMS tumors. Inhibition of CAV1 function 
could contribute to aberrant cell proliferation, leading to 
ARMS development. 
RESULTS
CAV1 is down-regulated in ARMS cell lines and 
tumor samples
We and others have previously shown down-
regulation of CAV1 in ARMS cell lines [12-13]. To further 
determine the expression levels of CAV1 in RMS cell lines 
and patients, we analyzed its expression by western blot in 
a panel of human cell lines and by immunohistochemistry 
(IHC) in a tissue microarray (TMA) of 70 patients (Figure 
1 and Supplementary Table S1). Most of the ARMS cell 
lines tested had very low or undetectable levels of CAV1 
(Figure 1A). In the TMA (Figure 1B), CAV1 expression 
Figure 1: CAV1 expression in rhabdomyosarcomas. 
(A) Western blot showing CAV1 expression (at high and low 
exposure) in different ARMS (RH4, RH41, RH28, RMS13 
RH30 -PAX3/FOXO1- and CW9019 -PAX7/FOXO1-), ERMS 
(RH36, RD), Botryoid (RUCH2) and Rhabdoid (A204) cell 
lines, using a Ewing sarcoma cell line (TC252) as a positive 
control, (B) CAV1 staining from a pleural ARMS sample (right 
panel), representative of the absence of CAV1 expression in 
these patients, and from a pelvic ERMS in stage 4 (left panel), 
representative of high expression of CAV1. Scale bars 100 µm 
and 50 µm for the higher magnification.
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was detected mostly in ERMS patients (28/39) and was 
localized in the cytosol and plasma membrane. Barely 
any expression was found in ARMS patients (2/12). 
Expression in other forms of RMS was variable (9/19). 
As shown in supplementary Table S1, not enough clinical 
information was available to establish any significant 
statistical correlation. 
CAV1 is silenced in ARMS cells by epigenetic 
mechanisms
CAV1 has been reported to be up-regulated 
by the DNA methyltransferase inhibitor 5-AZA-2’-
deoxycytidine (5-aza-dC) in several types of cancer [14]. 
Moreover, hypermethylation of the CAV1 promoter in 
human cancer has also been shown [15-17]. Analysis of 
DNA methylation in the CAV1 gene promoter (Figure 
Figure 2: Analysis of DNA methylation in the CAV1 gene promoter. (A) Representation of the CAV1 gene in the UCSC Genome 
Browser. The promoter-associated CpG island is boxed. The tracks indicate the position of CpG sites and Infinium 450K methylation arrays 
(HCT-116 Stanford), (B) Enlarged display of the CpG island. The region analyzed for DNA methylation is boxed, (C) Region analyzed 
for DNA methylation by bisulfite sequencing, (D) DNA methylation levels of the CpGs analyzed by bisulfite sequencing (E) Detail of the 
electropherogram showing three CpGs differentially methylated enclosed in a box in panel D. Methylation level of each CpG is indicated at 
the bottom of the sequence (reverse strand) using the same code of panel D, RT-PCR (F) and Western Blot (G) 72h after 5-aza-dC treatment 
in RH4 cells. 
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2A-C) of RMS cell lines and tumor samples showed 
hypermethylation in the promoter-associated CpG island 
in 5 out of 6 ARMS cell lines but in any of the other cell 
lines used in the experiment nor in the two ARMS tumor 
samples (Figure 2D-E and Supplementary Figure S1). 
Treatment of RH4 cells with increasing concentrations 
of 5-aza-dC induced re-expression of CAV1 mRNA and 
protein (Figure 2F and G). Similar results were obtained 
in other three ARMS cell lines (RH41, RH28 and RMS13) 
(Supplementary Figure S2).
Over-expression of CAV1 suppresses 
tumorigenicity of ARMS cells
In order to explore the role of CAV1 in the 
progression of ARMS we stably transfected RH4, RH41 
and RH28 cells with the expression vector pCMV6-
CAV1. Over-expression of CAV1 was confirmed in 
several selected clones by western blot (Figure 3A, 
Supplementary Figure S3A and Supplementary Figure 
S4). Changes in CAV1 protein expression were also 
confirmed by immunofluorescence, where over-expressing 
Figure 3: Effects of CAV1 transfection in the RH4 cell line. (A) Western Blot showing expression of CAV1 on isolated clones, 
(B) Inmunofluorescence showing expression and localization of CAV1 in the plasma membrane of RH4 transfected cells, Scale bars 10µm, 
(C) Clonogenic assay using the RH4 model showing a decrease in the clonogenic capacity in the CAV1 transfected cells (CMV stands 
for empty vector transfected cells and CAV refers to CAV1 transfected cells, the number indicates the clone). Statistical significance was 
assessed by the Student’s t test: **p ≤ 0.001 and ***p≤0.0001.
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cells demonstrated increased cytoplasm and membrane 
localization of CAV1 following transfection (Figure 3B). 
Moreover, as a result of CAV1 reintroduction, clonogenic 
growth was significantly affected (Figure 3C and Figure 
S3B). It is well known that the biological behavior of 
a tumor is related to the degree of differentiation of its 
cells, and a lower degree of differentiation generally 
correlates with greater tumor growth. Accordingly, as a 
consequence of CAV1 transfection we observed elongated 
cell morphology and appearance of cross-striations in 
some cells, consistent with a more differentiated myogenic 
phenotype (Figure 4A). This effect was further highlighted 
Figure 4: RH4 rhabdomyosarcoma cells expressing CAV1 show an increased capacity for initiate differentiation 
process, but they die before fully completing it. (A) CAV1 expressing RH4 cells cultured in differentiation media (RPMI medium 
without serum) for 72 h change their morphology by the acquisition of an elongate form (arrows), (B) Wild-type RH4 rhabdomyosarcoma 
cells grow normally in differentiation conditions up to 120 h, but transfected cells expressing CAV1 die, (C) Cytofluorometric plots 
showing the acquisition of the vital dye DiOC6(3) which accumulates in mitochondria maintaining their characteristic membrane potential 
(Δψm) and the cell death marker Propidium Iodide (PI) who only enters in cells whose plasma membrane barrier is broken. RH4/CAV-10 
population shows a clear shift towards losing both the Δψm and the membrane integrity, hallmarks of apoptosis, (D) Cell cycle analysis by 
means of cytofluorometric measurement of DNA-binding dye PI content in fixed cells. Cells cultured in differentiation conditions show a 
trend to be arrested in G2/M phase of the cell cycle. The G2/M blockade becomes significant in RH4/CAV-7 line. CAV1 expressing cells 
show a marked increase of the number of cells with a DNA content inferior of the G1 phase (apoptotic). Statistical significance was assessed 
by the Student’s t test: ***p ≤ 0.0001. Scale bars 50 μm. 
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in differentiation conditions on RH4 and RH28 models 
(Figure 4B and Supplemental Figure S5A). Additionally, 
under differentiation conditions most of CAV1 transfected 
cells failed to maintain the polarization of the outer 
mitochondrial membrane and the barrier of the plasma 
membrane (as visualized by cytofluorometric analysis with 
the probes DiOC6(3) and Propididum Iodide (PI) (Figure 
4C and Supplemental Figure S5B). When cultivated in 
differentiation conditions (Figure 4D, Supplementary 
Figure S5C and Supplementary Figure S6), CAV1-
transfected cells significantly increased the amount 
of apoptotic cells. More interestingly, differentiation 
conditions led to an increase of G2/M cells (assumed as 
G2 cells as microscopical observation showed not dividing 
cells) especially significant in clone 7. Combination of the 
DiOC6(3)-PI viability assay with the cell permeable DNA 
dye Hoechst-33342 pointed that at least part of the dying 
cells start apoptosis from G2 phase (data not shown). 
Most importantly, in vivo experiments on the RH4 
model showed that, 40 days after s.c. injection into nude 
mice, CAV1–derived xenografts were significantly smaller 
(p ≤ 0.05) than those induced by control cells (Figure 5A). 
Immunohistochemical analyses of paraffin-embedded 
tumors showed no detectable CAV1 expression in control 
Figure 5: CAV1 delays ARMS in vivo tumor growth. (A) Graphic comparing tumor size (mm3) in the RH4/CAV1 model (Control 
states for RH4 and RH4/CMV, CAV1 transfected cells states for RH4/CAV-7 and RH4/CAV). CAV1 expressing cells grow significantly less 
than control cells, (B) Histopathology was examined by hematoxilin/eosin (H&E) and CAV1 expression by IHC staining, (C) proliferative 
capacity of the tumors was evaluated by Ki-67 staining. Positive cells were counted and percentage represented in the graphic, (D) 
differentiation state of the tumor was evaluated by MyHC staining. Positive cells were counted and percentage was represented in the 
graphic. Statistical significance was assessed by the Student’s t test: *** p<0.0001. Scale bars 50 µm.
Oncotarget9750www.impactjournals.com/oncotarget
xenografts compared with the highly positive staining of 
CAV1–derived tumors (Figure 5B). Interestingly, CAV1-
derived xenografts showed significant less Ki-67, a known 
marker of proliferation. On the other hand CAV1-derived 
xenografts showed more Myosin Heavy Chain (MyHC) 
staining (Figure 5C-D) suggesting tumors are less 
proliferative and more prone to differentiate. Altogether, 
these data show that CAV1 is a key negative effector of 
tumorogenesis, necessary for the development of the 
transformed phenotype in ARMS sarcomagenesis.
Because PAX/FOXO1 proteins block terminal 
differentiation in ARMS [5], we analyzed possible 
changes in these proteins as a consequence of CAV1 
transfection. No significant changes were observed 
under proliferation (Figure 6A) or under differentiation 
conditions (Figure 6B). However, in clones 7 and 10, 
where higher phenotypic alterations were observed, under 
differentiation conditions FOXO1 levels were decreased. 
ERK dephosphorylation is key at the onset of myogenesis 
[14]. Furthermore, CAV1 is known to block MAPK 
signaling as part of its tumor suppressive activities [15]. 
Therefore, in order to go deeply into the mechanism by 
which CAV1 delays tumor growth in ARMS we sought 
to analyze the effects of CAV1 expression on MAPK 
signaling. Results showed that indeed, CAV1 expression 
caused ERK dephosphorylation under proliferating 
conditions (Figure 6A). This effect was further accentuated 
in the majority of the clones, except for clone 9, when 
cells were grown under differentiation conditions (Figure 
6B). Moreover, a known marker of differentiation, CAV3, 
was increased both under proliferation and differentiation 
conditions (Figure 6A and 6B). 
In order to demonstrate the CAV1 dependent pro-
differentiation effects on ARMS cells we tested the 
modulation of myogenin in the early and MyHC in the 
late phase of differentiation. As shown in Supplementary 
Figure S7, in comparison to controls CAV1 transfected 
cells showed an upregulation of myogenin up to 72 hours 
followed by an important decrease at 120 hours. MyHC 
appeared mostly at 120 hours (Supplementary Figure S7). 
Overall our results strongly suggest that CAV1 
expression delays ARMS cell growth, at least in part, by 
blocking ERK signaling, turning malignant cells toward 
a more permissive state for differentiation and cell death. 
DISCUSSION
Testing for the expression of CAV1 in several 
sarcoma cell lines we found that its expression in most 
alveolar rhabdomyosarcoma cells was very low or 
undetectable [12]. Because proliferating myoblasts express 
CAV1 [16], we postulated that very low or no expression 
on proliferating tumor cells suggest that CAV1 would 
have suppressive activities on ARMS. In fact, a tumor 
suppressor role for CAV1 has been clearly demonstrated 
in several types of cancer [17-19] including sarcomas [20]. 
To test our hypothesis we validated first the expression 
levels of CAV1 on a broader number of cell lines and in 
tumor samples. Results confirmed that most ARMS cell 
lines, except for CW9019 (PAX7-FOXO1), and patients 
presented barely any expression of CAV1. This result 
might suggest that downregulation of CAV1 correlates 
specifically with PAX3-FOX1 expression. Unfortunately, 
we did not possess exact information about the type of 
translocation in our ARMS patients cohort. Analysis of 
this issue in further patient cohorts will help to elucidate 
whether this relationship exist. 
CAV1 can be negatively regulated by several means. 
Figure 6: CAV1 affects ERK phosphorylation and promotes changes in CAV3. (A) Western blot showing PAX3-FOXO1, 
FOXO1, CAV1, ERK, phospho-ERK and CAV3 levels in cells grown in proliferating conditions or (B) grown under differentiation 
conditions.
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For example, DNA methylation, that is an epigenetic 
mechanism of transcriptional regulation. Deregulation 
of DNA methylation in cancer results in inappropriate 
silencing of tumor suppressor genes by hypermethylation 
of the promoter region and oncogene overexpression by 
loss of methylation [21-23]. Thus, hypermethylation of 
CAV1 promoter has been shown to maintain it at low 
expression levels in some types of cancer such as breast 
and colon [24-25]. Therefore, we tested this possibility in 
several cell lines and tumor samples. Bisulfite sequencing 
showed heavy hypermethylation of the CAV1 promoter 
in ARMS cell lines. However, although no expression 
of CAV1 was detected in tumor samples no methylation 
was observed in its promoter, suggesting that promoter 
hypermethylation is a secondary event to gene silencing 
which would be induced by other mechanisms [26]. In this 
regard, one possibility is that expression of CAV1 might 
be regulated by microRNAs (miRNAs). In fact several 
miRNAs such as miR-124, miR-203, miR-199a and miR-
802 had been found to directly suppress CAV1 in other 
tumors [27-31]. Among them miR-199a is the only one 
found highly expressed in ARMS [32] suggesting that 
this miRNA could be a good candidate as responsible 
for CAV1 downregulation in the tumor samples studied. 
Whether miR-199a targets CAV1 in ARMS deserves 
therefore further work. Another possibility is proteasomal 
degradation. Actually, CAV1 had also been shown to 
be degraded by the proteasome [33]. Hence, activity of 
stromal factors acting on proteasome pathways in tumor 
cells can occur in ARMS patients and be responsible of 
CAV1 downregulation.
Our gain of function experiments clearly 
demonstrated that CAV1 had suppressive activities in 
ARMS cells both in vitro and in vivo, effects that were 
highlighted when cells were grown under differentiation 
conditions. Mitochondrial membrane potential (Δψm) 
dissipation is a well known process in apoptosis signaling, 
whereas the influx of Propidium Iodide inside the cells is 
a sign of loss of cationic pumps shared by late apoptotic 
cells and necrotic ones. Different end-point analyses 
(data not shown) suggests that the dissipation of the 
mitochondrial membrane potential precedes the loss 
of the plasma membrane barrier, indicating that CAV1 
transfected cells triggered apoptosis in differentiation 
conditions.
One of the key features of ARMS is its incapacity to 
proceed through terminal differentiation [4]. Furthermore, 
the degree of myogenic differentiation in these tumors 
has been shown to inversely correlate with proliferation, 
migration and invasion [34]. Our results strongly suggest 
that CAV1 mediates tumor suppression, at least in part, 
by turning tumor cells more prone to differentiate. 
Accordingly, CAV3, a marker of differentiation [35] was 
highly upregulated in CAV1 transfected cells. Likewise, 
dephosporylation of ERK1/2, necessary for cell fusion 
[36] prior to myotube formation and higher expression 
of myosin heavy chain proteins, exclusive of myotubes 
[37] were also observed. Interestingly, FOXO1 levels 
were reduced in clones 7 and 10 paralleling phenotypic 
alterations in cells cultured under differentiation 
conditions. In agreement with these results, FOXO1 has 
been shown to delay and negatively regulate skeletal 
myoblast differentiation [38]. 
Recently Faggi et al. reported that overexpression of 
CAV1 leads to rhabdomyosarcoma cell proliferation [39], 
using the RH30 cell line as a model of high expression 
of CAV1. These reported results argue against the 
conclusions of our study. Nevertheless, in our panel of 
cells, RH30 and RMS13 (cells that come from the same 
patient) showed fairly low levels of CAV1. Furthermore, 
treatment of RMS13 with 5-aza-dC induced re-expression 
of CAV1 mRNA and protein. So, in our opinion this cell 
line is not representative of highly expressed CAV1 and 
therefore our panel of ARMS cells reflects better the role 
of CAV1 as a putative tumor suppressor in ARMS.
In summary, our results suggest that CAV1 could 
function as a potent tumor suppressor in ARMS tumors. 
Inhibition of CAV1 function therefore could contribute to 
aberrant cell proliferation, leading to ARMS development. 
Finally, we propose that mimicking CAV1 function may 
be of therapeutic use for the treatment of ARMS.
MATERIALS AND METHODS
Cell culture, stable transfection and treatments
RH4 and RH30 (kindly provided by Dr. Peter 
Houghton, The Research Institute Nationwide Children’s 
Hospital, Columbus, Ohio), RH28, RMS13, RH36 and 
Ruch2 (kindly provided by Dr. Beat Schäfer, Department 
of Oncology and Children’s Research Center, University 
Children’s Hospital, Zurich, Switzerland), CW9019 
(kindly provided by Dr. Frederic Barr, National Cancer 
Institute, Bethesda, MD, USA), RH41, RD and A204 
(bought from DSMZ, Libniz Institute DSMZ-German 
Collection of Microorganisms and Cell Cultures, 
Braunschwieg Germany) and TC252 cell lines (kindly 
provided by Dr. Heinrich Kovar, Children’s Cancer 
Research Institute (CCRI), Viena, Austria) were cultured 
in RPMI 1640 (Invitrogen) supplemented with 10% heat-
inactivated fetal bovine serum (Invitrogen). All cell lines 
were incubated at 37°C in a humidified atmosphere of 
5% CO2 in air. Exponentially growing cells within two 
sequential passages were used for all experiments. Cells 
were transfected using Lipofectamine 2000 (Invitrogen) 
following the protocols of the manufacturer. Transfected 
cells were selected with neomycin [0.6 mg/m1 for RH4 
0.4 mg/ml for RH41, Invitrogen] for 14 days. pCMV6-
CAV1 was bought from OriGene Technologies, Medical 
Center, Rockville, Maryland. Antibiotic-resistant pools 
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and individual clones were isolated for further analysis 
and maintained in the presence of neomycin (0.4 mg/ml 
or 0.6 mg/ml). For differentiation experiments cells were 
serum deprived for 72h. All cell lines were treated with 
5-AZA-2’-deoxycytidine (5-aza-dC) (Sigma) to allow 
global CpG demethylation. 2×105 cells/well were plated 
in 6-well dishes and treated after 24h with 1, 2.5 and 5 μM 
5-aza-dC for 72h. Drug was added every 24h. 
Bisulfite sequencing
Caveolin 1 CpG island methylation was analyzed 
by bisulfite sequencing. Briefly, 300 ng of genomic 
DNA were converted with EZ DNA methylation 
kitTM (Zymo Research), according to manufacturer’s 
instructions. Two different fragments spanning a total 
of 16 CpGs (Figure 2) were amplified by a nested PCR 
performed in triplicate and pooled before purification 
using JETQUICK PCR Spin KIT (Genomed), to ensure 
a representative methylation profile. The PCR products 
were sequenced using specific primers at GATC Biotech 
service. The primers used for the PCR amplifications 
were designed using MethPrimer and Bisearch [40] are: 
external PCR (GAGGTGGGAAGGGATGGTTTA, 
AAATTTCCCTAAACTATACTTTAA), internal 
PCR A (GTTGTTTATATTGGGTATTTTTG, 
TCTAAACACATCCCCAAAATTC), internal 
PCR B (ATTTTTGTTGAGATGATGTATTG, 
TCTAAACACATCCCCAAAATTC). Lollipop 
representations were generated using the Methylation 
Plotter web tool [41]. 
Clonogenic assay
For clonogenic assays, 500 cells/well were seeded in 
6-well plates. When colonies reached saturation (14 days 
after seeding) cells were fixed with 4% formaldehyde 
for 30 minutes, washed with Dulbeco’s PBS (DPBS), 
stained with violet crystal for 20 minutes and washed with 
water. Plates were scanned and colonies counted. Images 
reflect representative results of at least three independent 
experiments. 
Flow cytometry
For the simultaneous quantification of plasma 
membrane integrity and mitochondrial transmembrane 
potential (Δψm), living cells were collected and 
stained with 1 μg/mL propidium iodide (PI, which 
only incorporates into dead cells, from Molecular 
Probes) and 40 nM of the Δψm-sensitive dye 
3,3’-dihexyloxacarbocyanine iodide (DiOC6(3), from 
Sigma-Aldrich) for 30 min at 37 °C. The cell-permeable 
DNA-binding dye Hoechst-33342 (Molecular Probes) 
were also added (10 μg/mL final concentration) for 
determining the cell-cycle status of live or dying cells.
For cell cycle analysis, cells were fixed in 70% ice-
cold ethanol and labeled with 50 µg/ml PI in the presence 
of 500 µg/ml RNAse (Sigma-Aldrich). Cytofluorometric 
determinations were performed by means of a Gallios 
flow cytometer and data were statistically evaluated using 
Kaluza software (Beckman Coulter). Only the events 
characterized by normal forward scatter (FSC) and side 
scatter (SSC) parameters were included in subsequent 
analyses.
Western Blot analysis
Cells were lysed with radioimmunoprecipitation 
assay buffer (RIPA Bufer, Thermo Scientific) containing 
protease inhibitors (Complete, Mini; Protease Inhibitor 
Cocktail Tablets, Roche) and phosphatase inhibitors 
(PhoStop, Phospatase Inhibitor Cocktail Tablets, Roche) 
and centrifuged at 13000×g, at 4ºC, for 20 minutes. The 
protein content of the supernatants was determined with 
BCA assay system (Pierce). Lysate aliquots (50 μg) 
were resolved by 8%, 10% or 12% (depending on the 
protein molecular weight) SDS-PAGE and transferred 
onto nitrocellulose membranes. After blocking with 5% 
skimmed milk in PBS containing 0.2% Tween 20 at 
room temperature for 1 hour, membranes were incubated 
overnight at 4ºC with the appropriate primary antibody 
(CAV1 #610059 from BD, FoxO1 #2880, ERK1/2 #4695, 
phospho-ERK1/2 #4376 from Cell Signaling Technology; 
CAV3 #sc5310 and Myogenin #sc-12732 from Santa 
Cruz; MyHC MF 20 from Developmental Studies 
Hybridoma Bank). Blots were then incubated at room 
temperature for 1 hour with a horseradish peroxidase–
conjugated secondary antibody and the peroxidase 
activity was detected by enhanced chemiluminescence 
(Pierce) following the instructions of the manufacturer. 
Immunodetection of β-actin (#ab49900) from Abcam was 
used as a loading reference.
Xenografts
In vivo tumors were induced with subcutaneous 
injections of RH4/CAV1 model (3 ×106 cells), resuspended 
in 100μL of Matrigel Matrix (BD), in the hind legs of 10 
athymic nude mice purchased from Charles River (Left 
flank RH4, right flank RH4/CAV-7 n=5; Left flank RH4/
CMV, right flank RH4/CAV n=5). When the tumor reached 
a mean volume of about 1cm3 mice were euthanized and 
the tumor was removed for further analysis. Tumors 
were fixed in 4% paraformaldehyde and embedded 
in paraffin. Tumor volumes were calculated using the 
formula V= (1/2)a×b2, where a is the longest tumor axis, 
and b is the shortest tumor axis. Data are given as mean 
±SD. Statistical analysis was done by unpaired Student’s 
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t test. Animal care procedures were followed according 
to the Institutional Guidelines for the Care and Use of 
Laboratory Animals. Ethics approval was provided by the 
locally appointed ethics committee from the Biomedical 
Research Institute (IDIBELL), Barcelona, Spain. 
Immunohistochemistry and Immunofluorescence
Immunohistochemical techniques were done 
as previously described [42]. Expression of CAV1 
in xenografts was analyzed using a rabbit polyclonal 
antibody (CAV1 #610059, BD). Proliferation marker 
Ki-67 and differentiation marker MyHC were analyzed 
using rabbit polyclonal antibody (Ki-67 #18-0191Z, 
Life Technologies) and Mouse monoclonal antibody 
(eMHC F1652 Developmental Studies Hybridoma Bank). 
Immunofluorescence of ARMS cells was performed as 
described [43]. Photographs were taken with a Leica 
TCS SP5 spectral confocal microscope (argon, 405 diode 
and DPSS561) using a lambda blue 63×1.35 numerical 
aperture oil objective. Images were analyzed with Image 
J software (freely available from the National Institutes 
of Health (NIH) at the address http://rsb.info.nih.gov/ij/).
Reverse Transcription-PCR (RT-PCR)
Total RNA (2μg), extracted using the Total 
RNA Isolation Kit (NucleoSpin RNA II, Macherey-
Nagel), was used for cDNA synthesis with SuperScript 
II Reverse Transcriptase (Invitrogen). Primers 5’- 
ACAAGCCCAACAACAAGG-3’ (forward) and 5’- 
ATCGGGATGCCAAAGAGG-3’ (reverse) were used for 
amplification of Caveolin-1 (259 bp); and for β-Actin (432 
bp), 5’- CGGGACCTGACTGACTACCTC-3’ (forward) 
and 5’- CTTCATTGTGCTGGGTGC-3’ (reverse) from 
Invitrogen. Amplification of Caveolin-1 was adjusted 
at an annealing temperature of 58.4 °C and 59.5 °C for 
β-Actin. For each set of primers, the numbers of cycles 
was adjusted so that the reaction end points fell within the 
exponential phase of product amplification, thus providing 
a semi-quantitative estimate of relative mRNA abundance. 
RT-PCR determinations were carried out thrice for each 
relevant transcript. 
Quantitative Real Time PCR
Total RNA was extracted using the Total RNA 
Isolation Kit (NucleoSpin RNA II, Macherey-Nagel). 2 μg 
of RNA were used for cDNA synthesis with SuperScript 
II Reverse Transcriptase (Invitrogen). Quantitative 
reverse transcription-PCR (qRT-PCR) was performed 
under universal cycling conditions on an ABI 7300HT 
instrument (Applied Biosystems) using commercially 
available CAV1 probe (Hs00971716_m1) and mastermix 
(all from Life Technologies). Cycle threshold (CT) values 
were normalized to Beta Actin (ACTB). Experiments 
were performed at least three times and in triplicates. 
Relative expression level of the target gene among the 
different samples was calculated using the ΔΔCT method 
[44]. Mean values and standard deviations were calculated 
based on the results of three biological replicates at least.
Statistical Analysis
Data were analyzed for statistical significance using 
Student’s t test. Unless otherwise stated, experiments were 
performed thrice; P ≤ 0.05 was regarded as significant.
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